PD-L1 expression and survival rates using TPS and CPS for nivolumab-treated head-and-neck cancer
T Ito, I Okamoto, K Tokashiki, H Sato… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: This study investigated the expression and survival rates of programmed
cell death ligand 1 using the tumor proportion score (TPS) and combined positive score …
cell death ligand 1 using the tumor proportion score (TPS) and combined positive score …
Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab
I Okamoto, H Sato, K Tsukahara - Auris Nasus Larynx, 2020 - Elsevier
Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all
patients before administering nivolumab. The aim of the present study is to clarify the …
patients before administering nivolumab. The aim of the present study is to clarify the …
Role of programmed death‐ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous …
Background It was reported that treatment outcomes of the salvage chemotherapy (SCT)
following nivolumab are fairly good compared with those of nivolumab itself. However …
following nivolumab are fairly good compared with those of nivolumab itself. However …
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with …
Objectives We report 2-year results from CheckMate 141 to establish the long-term efficacy
and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with …
and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with …
Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer
Y Sato, N Fukuda, YU Fujiwara, X Wang, T Urasaki… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
Abstract CT021: tumor-associated immune cell PD-L1 expression and peripheral immune profiling: analyses from CheckMate 141
RL Ferris, G Blumenschein, K Harrington, J Fayette… - Cancer Research, 2017 - AACR
Introduction: In the phase 3 study CheckMate 141 (NCT02105636), patients with platinum-
refractory head and neck squamous cell carcinoma treated with nivolumab (NIVO) had …
refractory head and neck squamous cell carcinoma treated with nivolumab (NIVO) had …
[HTML][HTML] Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma
I Okamoto, K Tsukahara, H Sato - Scientific Reports, 2022 - nature.com
Nivolumab, an immune checkpoint inhibitor, is beneficial to patients with platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However …
recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However …
[HTML][HTML] Prognostic markers in head and neck cancer patients treated with nivolumab
D Nishikawa, H Suzuki, Y Koide, S Beppu, S Kadowaki… - Cancers, 2018 - mdpi.com
To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1
antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated …
antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated …
Five-year follow-up of patients with head and neck cancer treated with nivolumab and long-term responders for over two years
M Matsuo, R Yasumatsu, M Masuda, M Yamauchi… - in vivo, 2022 - iv.iiarjournals.org
Background/Aim: A long-term effect has been confirmed in clinical practice since the
introduction of nivolumab for treating various malignant tumors. A similar phenomenon is …
introduction of nivolumab for treating various malignant tumors. A similar phenomenon is …
A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab+ cisplatin/carboplatin+ fluorouracil) as first-line …
Background Patients (pts) with recurrent/metastatic (R/M) SCCHN have a poor prognosis.
Addition of cetuximab to platinum and 5-FU (Extreme regimen) improved overall survival …
Addition of cetuximab to platinum and 5-FU (Extreme regimen) improved overall survival …
Related searches
- nivolumab for head neck cancer
- survival rates pd l1
- head and neck pd l1
- overall survival neck cancer
- head and neck cell carcinoma
- head and neck diagnostic assays
- long term neck cancer
- pd l1 immune cell
- prognostic markers neck cancer
- pd l1 diagnostic assays
- metastatic head efficacy of nivolumab
- salvage chemotherapy death ligand
- death ligand cell carcinoma
- death ligand treatment outcome
- patients with head neck cancer
- pd l1 neck cancer